Afatinib is an Orally Active EGFR/HER2 Dual Inhibitor for Cancer Research
The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). These structurally related receptors…